Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2023 through 2029. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Targeted Drug EGFR RTK Inhibitors for NSCLC players cover Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals and Glenmark Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2023 through 2029. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Targeted Drug EGFR RTK Inhibitors for NSCLC is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Targeted Drug EGFR RTK Inhibitors for NSCLC players cover Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals and Glenmark Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Icotinib
- Gefitinib
- Erlotinib
- Afatinib
- Osimertinib
- Brigatinib
- Other
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Beta Pharma
- AstraZeneca
- Natco Pharma
- Qilu Pharmaceutical
- Genentech (Roche Group)
- Mylan
- Teva
- OSI Pharmaceuticals
- Glenmark Pharmaceuticals
- Beacon Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- ARIAD Pharmaceuticals (Takeda)
- Genvio Pharma Limited
- Drug International Limted
- Everest Pharmaceuticals
- Incepta Pharmaceuticals Limited
- Cipla Pharma
- Dr Reddy's Laboratories
- Zydus Cadila
- Hetero Drugs
- Intas Pharmaceuticals
- Alkem Laboratories
- RPG Life Sciences
- Fresenius Kabi India
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2029
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
2.2.1 Icotinib
2.2.2 Gefitinib
2.2.3 Erlotinib
2.2.4 Afatinib
2.2.5 Osimertinib
2.2.6 Brigatinib
2.2.7 Other
2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
2.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
3 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Players
3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2018-2023)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BY REGIONS
4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2018-2023)
4.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023)
5.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
5.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023)
6.2 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
6.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC by Country (2018-2023)
7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC by Region (2018-2023)
8.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
8.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Regions (2024-2029)
10.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Regions (2024-2029)
10.1.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2024-2029)
10.2.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.2 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.3 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.4 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2024-2029)
10.3.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.3 Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.5 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.6 Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2024-2029)
10.4.1 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.2 France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.3 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.4 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.5 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2024-2029)
10.5.1 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.2 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.3 Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.4 Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.5 GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Type (2024-2029)
10.7 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Beta Pharma
11.1.1 Beta Pharma Company Information
11.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Beta Pharma Main Business Overview
11.1.5 Beta Pharma Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Qilu Pharmaceutical
11.4.1 Qilu Pharmaceutical Company Information
11.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Qilu Pharmaceutical Main Business Overview
11.4.5 Qilu Pharmaceutical Latest Developments
11.5 Genentech (Roche Group)
11.5.1 Genentech (Roche Group) Company Information
11.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genentech (Roche Group) Main Business Overview
11.5.5 Genentech (Roche Group) Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 OSI Pharmaceuticals
11.8.1 OSI Pharmaceuticals Company Information
11.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 OSI Pharmaceuticals Main Business Overview
11.8.5 OSI Pharmaceuticals Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Beacon Pharmaceuticals
11.10.1 Beacon Pharmaceuticals Company Information
11.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Beacon Pharmaceuticals Main Business Overview
11.10.5 Beacon Pharmaceuticals Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Pfizer Main Business Overview
11.12.5 Pfizer Latest Developments
11.13 ARIAD Pharmaceuticals (Takeda)
11.13.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.13.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.14 Genvio Pharma Limited
11.14.1 Genvio Pharma Limited Company Information
11.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Genvio Pharma Limited Main Business Overview
11.14.5 Genvio Pharma Limited Latest Developments
11.15 Drug International Limted
11.15.1 Drug International Limted Company Information
11.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Drug International Limted Main Business Overview
11.15.5 Drug International Limted Latest Developments
11.16 Everest Pharmaceuticals
11.16.1 Everest Pharmaceuticals Company Information
11.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Everest Pharmaceuticals Main Business Overview
11.16.5 Everest Pharmaceuticals Latest Developments
11.17 Incepta Pharmaceuticals Limited
11.17.1 Incepta Pharmaceuticals Limited Company Information
11.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Incepta Pharmaceuticals Limited Main Business Overview
11.17.5 Incepta Pharmaceuticals Limited Latest Developments
11.18 Cipla Pharma
11.18.1 Cipla Pharma Company Information
11.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Cipla Pharma Main Business Overview
11.18.5 Cipla Pharma Latest Developments
11.19 Dr Reddy's Laboratories
11.19.1 Dr Reddy's Laboratories Company Information
11.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Dr Reddy's Laboratories Main Business Overview
11.19.5 Dr Reddy's Laboratories Latest Developments
11.20 Zydus Cadila
11.20.1 Zydus Cadila Company Information
11.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Zydus Cadila Main Business Overview
11.20.5 Zydus Cadila Latest Developments
11.21 Hetero Drugs
11.21.1 Hetero Drugs Company Information
11.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Hetero Drugs Main Business Overview
11.21.5 Hetero Drugs Latest Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Information
11.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Intas Pharmaceuticals Main Business Overview
11.22.5 Intas Pharmaceuticals Latest Developments
11.23 Alkem Laboratories
11.23.1 Alkem Laboratories Company Information
11.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Alkem Laboratories Main Business Overview
11.23.5 Alkem Laboratories Latest Developments
11.24 RPG Life Sciences
11.24.1 RPG Life Sciences Company Information
11.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 RPG Life Sciences Main Business Overview
11.24.5 RPG Life Sciences Latest Developments
11.25 Fresenius Kabi India
11.25.1 Fresenius Kabi India Company Information
11.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Fresenius Kabi India Main Business Overview
11.25.5 Fresenius Kabi India Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2029
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
2.2.1 Icotinib
2.2.2 Gefitinib
2.2.3 Erlotinib
2.2.4 Afatinib
2.2.5 Osimertinib
2.2.6 Brigatinib
2.2.7 Other
2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
2.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
3 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Players
3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2018-2023)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BY REGIONS
4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2018-2023)
4.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
4.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023)
5.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
5.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023)
6.2 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
6.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC by Country (2018-2023)
7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC by Region (2018-2023)
8.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023)
8.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Regions (2024-2029)
10.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Regions (2024-2029)
10.1.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2024-2029)
10.2.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.2 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.3 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.2.4 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2024-2029)
10.3.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.3 Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.5 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.6 Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2024-2029)
10.4.1 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.2 France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.3 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.4 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.4.5 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2024-2029)
10.5.1 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.2 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.3 Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.4 Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.5.5 GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Type (2024-2029)
10.7 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Beta Pharma
11.1.1 Beta Pharma Company Information
11.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Beta Pharma Main Business Overview
11.1.5 Beta Pharma Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Qilu Pharmaceutical
11.4.1 Qilu Pharmaceutical Company Information
11.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Qilu Pharmaceutical Main Business Overview
11.4.5 Qilu Pharmaceutical Latest Developments
11.5 Genentech (Roche Group)
11.5.1 Genentech (Roche Group) Company Information
11.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genentech (Roche Group) Main Business Overview
11.5.5 Genentech (Roche Group) Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 OSI Pharmaceuticals
11.8.1 OSI Pharmaceuticals Company Information
11.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 OSI Pharmaceuticals Main Business Overview
11.8.5 OSI Pharmaceuticals Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Beacon Pharmaceuticals
11.10.1 Beacon Pharmaceuticals Company Information
11.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Beacon Pharmaceuticals Main Business Overview
11.10.5 Beacon Pharmaceuticals Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Pfizer Main Business Overview
11.12.5 Pfizer Latest Developments
11.13 ARIAD Pharmaceuticals (Takeda)
11.13.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.13.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.14 Genvio Pharma Limited
11.14.1 Genvio Pharma Limited Company Information
11.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Genvio Pharma Limited Main Business Overview
11.14.5 Genvio Pharma Limited Latest Developments
11.15 Drug International Limted
11.15.1 Drug International Limted Company Information
11.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Drug International Limted Main Business Overview
11.15.5 Drug International Limted Latest Developments
11.16 Everest Pharmaceuticals
11.16.1 Everest Pharmaceuticals Company Information
11.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Everest Pharmaceuticals Main Business Overview
11.16.5 Everest Pharmaceuticals Latest Developments
11.17 Incepta Pharmaceuticals Limited
11.17.1 Incepta Pharmaceuticals Limited Company Information
11.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Incepta Pharmaceuticals Limited Main Business Overview
11.17.5 Incepta Pharmaceuticals Limited Latest Developments
11.18 Cipla Pharma
11.18.1 Cipla Pharma Company Information
11.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Cipla Pharma Main Business Overview
11.18.5 Cipla Pharma Latest Developments
11.19 Dr Reddy's Laboratories
11.19.1 Dr Reddy's Laboratories Company Information
11.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Dr Reddy's Laboratories Main Business Overview
11.19.5 Dr Reddy's Laboratories Latest Developments
11.20 Zydus Cadila
11.20.1 Zydus Cadila Company Information
11.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Zydus Cadila Main Business Overview
11.20.5 Zydus Cadila Latest Developments
11.21 Hetero Drugs
11.21.1 Hetero Drugs Company Information
11.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Hetero Drugs Main Business Overview
11.21.5 Hetero Drugs Latest Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Information
11.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Intas Pharmaceuticals Main Business Overview
11.22.5 Intas Pharmaceuticals Latest Developments
11.23 Alkem Laboratories
11.23.1 Alkem Laboratories Company Information
11.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Alkem Laboratories Main Business Overview
11.23.5 Alkem Laboratories Latest Developments
11.24 RPG Life Sciences
11.24.1 RPG Life Sciences Company Information
11.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 RPG Life Sciences Main Business Overview
11.24.5 RPG Life Sciences Latest Developments
11.25 Fresenius Kabi India
11.25.1 Fresenius Kabi India Company Information
11.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Fresenius Kabi India Main Business Overview
11.25.5 Fresenius Kabi India Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Icotinib
Table 3. Major Players of Gefitinib
Table 4. Major Players of Erlotinib
Table 5. Major Players of Afatinib
Table 6. Major Players of Osimertinib
Table 7. Major Players of Brigatinib
Table 8. Major Players of Other
Table 9. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 12. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2018-2023) & ($ Millions)
Table 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2018-2023)
Table 17. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions 2018-2023 & ($ Millions)
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)
Table 23. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country/Region (2018-2023) & ($ millions)
Table 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country/Region (2018-2023)
Table 25. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023) & ($ Millions)
Table 26. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)
Table 27. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 28. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 29. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 30. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 31. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023) & ($ Millions)
Table 32. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Table 33. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 34. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 35. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 36. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023) & ($ Millions)
Table 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)
Table 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 40. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 41. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 42. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 43. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Table 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 48. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 49. Key Market Drivers & Growth Opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 50. Key Market Challenges & Risks of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 51. Key Industry Trends of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 52. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 53. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Regions (2024-2029)
Table 54. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 55. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 56. Beta Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 57. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 58. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 59. Beta Pharma Main Business
Table 60. Beta Pharma Latest Developments
Table 61. AstraZeneca Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 62. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 63. AstraZeneca Main Business
Table 64. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. AstraZeneca Latest Developments
Table 66. Natco Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 67. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 68. Natco Pharma Main Business
Table 69. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Natco Pharma Latest Developments
Table 71. Qilu Pharmaceutical Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 72. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 73. Qilu Pharmaceutical Main Business
Table 74. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Qilu Pharmaceutical Latest Developments
Table 76. Genentech (Roche Group) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 77. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 78. Genentech (Roche Group) Main Business
Table 79. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Genentech (Roche Group) Latest Developments
Table 81. Mylan Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 82. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 83. Mylan Main Business
Table 84. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Mylan Latest Developments
Table 86. Teva Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 87. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 88. Teva Main Business
Table 89. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Teva Latest Developments
Table 91. OSI Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 92. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 93. OSI Pharmaceuticals Main Business
Table 94. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. OSI Pharmaceuticals Latest Developments
Table 96. Glenmark Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 97. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 98. Glenmark Pharmaceuticals Main Business
Table 99. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Glenmark Pharmaceuticals Latest Developments
Table 101. Beacon Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 102. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 103. Beacon Pharmaceuticals Main Business
Table 104. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 105. Beacon Pharmaceuticals Latest Developments
Table 106. Boehringer Ingelheim Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 107. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 108. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 109. Boehringer Ingelheim Main Business
Table 110. Boehringer Ingelheim Latest Developments
Table 111. Pfizer Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 112. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 113. Pfizer Main Business
Table 114. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Pfizer Latest Developments
Table 116. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 117. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 118. ARIAD Pharmaceuticals (Takeda) Main Business
Table 119. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 121. Genvio Pharma Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 122. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 123. Genvio Pharma Limited Main Business
Table 124. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Genvio Pharma Limited Latest Developments
Table 126. Drug International Limted Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 127. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 128. Drug International Limted Main Business
Table 129. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Drug International Limted Latest Developments
Table 131. Everest Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 132. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 133. Everest Pharmaceuticals Main Business
Table 134. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Everest Pharmaceuticals Latest Developments
Table 136. Incepta Pharmaceuticals Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 137. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 138. Incepta Pharmaceuticals Limited Main Business
Table 139. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Incepta Pharmaceuticals Limited Latest Developments
Table 141. Cipla Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 142. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 143. Cipla Pharma Main Business
Table 144. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Cipla Pharma Latest Developments
Table 146. Dr Reddy's Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 147. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 148. Dr Reddy's Laboratories Main Business
Table 149. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Dr Reddy's Laboratories Latest Developments
Table 151. Zydus Cadila Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 152. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 153. Zydus Cadila Main Business
Table 154. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 155. Zydus Cadila Latest Developments
Table 156. Hetero Drugs Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 157. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 158. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 159. Hetero Drugs Main Business
Table 160. Hetero Drugs Latest Developments
Table 161. Intas Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 162. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 163. Intas Pharmaceuticals Main Business
Table 164. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 165. Intas Pharmaceuticals Latest Developments
Table 166. Alkem Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 167. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 168. Alkem Laboratories Main Business
Table 169. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 170. Alkem Laboratories Latest Developments
Table 171. RPG Life Sciences Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 172. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 173. RPG Life Sciences Main Business
Table 174. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 175. RPG Life Sciences Latest Developments
Table 176. Fresenius Kabi India Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 177. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 178. Fresenius Kabi India Main Business
Table 179. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 180. Fresenius Kabi India Latest Developments
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Icotinib
Table 3. Major Players of Gefitinib
Table 4. Major Players of Erlotinib
Table 5. Major Players of Afatinib
Table 6. Major Players of Osimertinib
Table 7. Major Players of Brigatinib
Table 8. Major Players of Other
Table 9. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 12. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2018-2023) & ($ Millions)
Table 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2018-2023)
Table 17. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions 2018-2023 & ($ Millions)
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)
Table 23. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country/Region (2018-2023) & ($ millions)
Table 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country/Region (2018-2023)
Table 25. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023) & ($ Millions)
Table 26. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)
Table 27. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 28. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 29. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 30. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 31. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023) & ($ Millions)
Table 32. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Table 33. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 34. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 35. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 36. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2018-2023) & ($ Millions)
Table 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)
Table 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 40. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 41. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 42. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 43. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Table 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Table 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2018-2023) & ($ Millions)
Table 48. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Table 49. Key Market Drivers & Growth Opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 50. Key Market Challenges & Risks of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 51. Key Industry Trends of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 52. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 53. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Regions (2024-2029)
Table 54. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 55. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 56. Beta Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 57. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 58. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 59. Beta Pharma Main Business
Table 60. Beta Pharma Latest Developments
Table 61. AstraZeneca Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 62. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 63. AstraZeneca Main Business
Table 64. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. AstraZeneca Latest Developments
Table 66. Natco Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 67. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 68. Natco Pharma Main Business
Table 69. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Natco Pharma Latest Developments
Table 71. Qilu Pharmaceutical Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 72. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 73. Qilu Pharmaceutical Main Business
Table 74. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Qilu Pharmaceutical Latest Developments
Table 76. Genentech (Roche Group) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 77. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 78. Genentech (Roche Group) Main Business
Table 79. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Genentech (Roche Group) Latest Developments
Table 81. Mylan Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 82. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 83. Mylan Main Business
Table 84. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Mylan Latest Developments
Table 86. Teva Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 87. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 88. Teva Main Business
Table 89. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Teva Latest Developments
Table 91. OSI Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 92. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 93. OSI Pharmaceuticals Main Business
Table 94. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. OSI Pharmaceuticals Latest Developments
Table 96. Glenmark Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 97. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 98. Glenmark Pharmaceuticals Main Business
Table 99. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Glenmark Pharmaceuticals Latest Developments
Table 101. Beacon Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 102. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 103. Beacon Pharmaceuticals Main Business
Table 104. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 105. Beacon Pharmaceuticals Latest Developments
Table 106. Boehringer Ingelheim Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 107. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 108. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 109. Boehringer Ingelheim Main Business
Table 110. Boehringer Ingelheim Latest Developments
Table 111. Pfizer Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 112. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 113. Pfizer Main Business
Table 114. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Pfizer Latest Developments
Table 116. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 117. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 118. ARIAD Pharmaceuticals (Takeda) Main Business
Table 119. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 121. Genvio Pharma Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 122. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 123. Genvio Pharma Limited Main Business
Table 124. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Genvio Pharma Limited Latest Developments
Table 126. Drug International Limted Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 127. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 128. Drug International Limted Main Business
Table 129. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Drug International Limted Latest Developments
Table 131. Everest Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 132. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 133. Everest Pharmaceuticals Main Business
Table 134. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Everest Pharmaceuticals Latest Developments
Table 136. Incepta Pharmaceuticals Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 137. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 138. Incepta Pharmaceuticals Limited Main Business
Table 139. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Incepta Pharmaceuticals Limited Latest Developments
Table 141. Cipla Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 142. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 143. Cipla Pharma Main Business
Table 144. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Cipla Pharma Latest Developments
Table 146. Dr Reddy's Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 147. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 148. Dr Reddy's Laboratories Main Business
Table 149. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Dr Reddy's Laboratories Latest Developments
Table 151. Zydus Cadila Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 152. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 153. Zydus Cadila Main Business
Table 154. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 155. Zydus Cadila Latest Developments
Table 156. Hetero Drugs Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 157. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 158. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 159. Hetero Drugs Main Business
Table 160. Hetero Drugs Latest Developments
Table 161. Intas Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 162. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 163. Intas Pharmaceuticals Main Business
Table 164. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 165. Intas Pharmaceuticals Latest Developments
Table 166. Alkem Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 167. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 168. Alkem Laboratories Main Business
Table 169. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 170. Alkem Laboratories Latest Developments
Table 171. RPG Life Sciences Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 172. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 173. RPG Life Sciences Main Business
Table 174. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 175. RPG Life Sciences Latest Developments
Table 176. Fresenius Kabi India Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 177. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 178. Fresenius Kabi India Main Business
Table 179. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 180. Fresenius Kabi India Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2022)
Figure 8. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2022
Figure 10. Targeted Drug EGFR RTK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 12. Targeted Drug EGFR RTK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 14. Targeted Drug EGFR RTK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2022
Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player in 2022
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 20. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 21. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 23. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Value Market Share by Country in 2022
Figure 24. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region in 2022
Figure 29. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2022
Figure 30. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2022
Figure 31. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country in 2022
Figure 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Figure 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Figure 40. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 54. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 55. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 57. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 58. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 61. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 63. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 65. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 66. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 67. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 68. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 69. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 70. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 71. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 72. Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 75. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 78. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2022)
Figure 8. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2022
Figure 10. Targeted Drug EGFR RTK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 12. Targeted Drug EGFR RTK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 14. Targeted Drug EGFR RTK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2018-2023) & ($ Millions)
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2022
Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player in 2022
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 20. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 21. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2018-2023 ($ Millions)
Figure 23. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Value Market Share by Country in 2022
Figure 24. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region in 2022
Figure 29. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2022
Figure 30. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2022
Figure 31. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country in 2022
Figure 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Figure 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Figure 40. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 54. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 55. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 57. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 58. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 61. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 63. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 65. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 66. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 67. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 68. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 69. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 70. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 71. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 72. Spain Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 75. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2024-2029 ($ Millions)
Figure 78. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2024-2029)
